From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do… Read More
Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumours, into clinical development. Incubated at the BioInnovation Institute (BII) and seeded… Read More
Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease, announced preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme. The data were from preclinical models of… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. DDW’s Diana Spencer has selected five stand-out news headlines this week, which all relate to immunotherapy… Read More
News round-up for 1-5 May by DDW Digital Content Editor Diana Spencer. My five stand-out news headlines this week all relate to immunotherapy or immunomodulatory therapies for cancer, particularly advances in our understanding of how other factors in the body, i.e., vitamin D levels and the… Read More
Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET. Join this free webinar to… Read More
New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. The findings could inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with… Read More
New research indicates that for patients with advanced skin cancer, it may be important to maintain normal vitamin D levels when receiving treatment with immune checkpoint inhibitors. The findings are published in CANCER, a peer-reviewed journal of the American Cancer Society. Vitamin D has… Read More
UK company Plasticell and Singapore-based LambdaGen have entered into a strategic collaboration to exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of large gene cassettes into the human genome. The UK-Singapore partnership is in part financed by a EUREKA GlobalStars competitive… Read More
Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET. Join this free webinar to… Read More
Hosted by DDW and supported by BPS BioScience and ACROBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET. Join this free webinar to… Read More
Watch this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy. In this free webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life… Read More
This article is sponsored by Taconic. The cancer therapeutic landscape changed dramatically with the introduction of immune checkpoint inhibitors (ICIs) that target T cells and leverage a patient’s immune system. Success in targeting T cells as immunotherapy has prompted investigators to explore whether other immune cell… Read More
The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study… Read More
Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual… Read More
Listen to this article on the DDW Podcast: John Maher, Leucid Bio, tells Megan Thomas about his work and offers valuable advice to others in this field. MT: Where do you work, and can you tell us what you’re working on at the moment? JM: I am Chief Scientific Officer of a CAR… Read More
